Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Stone talks about his workIn this video, Richard Stone, MD, talks about his work in the Hematologic OncologyTreatment Center at Dana-Farber/Brigham and Women's Cancer Center.
More than 100
clinical trials are currently underway in the Center for Hematologic Oncology. The combined resources of our partner organizations within Dana-Farber/Harvard Cancer Center make us the largest cancer research center in the nation.
The leukemia team works to develop more effective, less toxic treatments for acute leukemia and related disorders, including myelodysplastic syndrome, chronic myeloid leukemia and myeloproliferative disorders.
Our clinical research focuses on understanding how leukemia cells develop and creating new ways to block their growth. We are also taking the innovative step of treating adult acute lymphoblastic leukemia (ALL) patients using treatments that have proved successful in pediatric patients.
Our lymphoma research focuses on translating laboratory findings into less toxic treatments. We are committed to investigating and understanding the genetic pathways that enable lymphoma cells to survive and manipulating them with targeted therapies to improve outcomes.
Our research program features a variety of trials specifically for chronic lymphocytic leukemia (CLL) patients, focusing on familial CLL, genomic studies and testing of novel therapies.
The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics encompasses a large team of laboratory-based and clinical scientists investigating more effective therapies for multiple myelomas. Promising new therapies are rooted in a "bench-to-bedside" approach, where laboratory discoveries are rapidly translated into the clinical setting as part of treatment.
The main goal of clinical research at the Bing Center for Waldenström's Macroglobulinemia is to take laboratory discoveries to the clinic, where they can benefit Waldenström's patients.
Trials include studies aimed at improving outcomes of patients undergoing biological therapies that attempt to destroy the tumor cells directly; evaluating supportive therapies; and examining the genetic basis of the disease.
New Patient Appointments
Clinical Trials Questions?